Artesunate/mefloquine in Brazil, India, and Malaysia. In 2012 a course of treatment cost 2.50 USD. It is not commercially available in the United States. Artesunate/mefloquine is a recommended treatment in Southeast Asia while in Africa artesunate/amodiaquine, artemether/lumefantrine, artesunate/sulfadoxine/pyrimethamine are often preferred. Artesunate/mefloquine Artesunate/mefloquine is a medication used to treat malaria. It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria. It is taken by mouth. Side effects are similar to the medications being used separately. Use is recommended as it decreases the possibility of either medications being used alone. Dose forms appropriate
Mefloquine with an increased risk of birth defects or miscarriages. The drug may be used during breastfeeding, though it appears in breast milk in low concentrations. The World Health Organization gives approval for the use of mefloquine in the second and third trimesters of pregnancy and use in the first trimester does not mandate termination of pregnancy. Mefloquine is metabolized primarily through the liver. Its elimination in persons with impaired liver function may be prolonged, resulting in higher plasma levels and an increased risk of adverse reactions. The mean elimination plasma half-life of mefloquine is between two and four weeks. Total